RIGL
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Rigel announced the availability of VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancerAug 13, 2026
- Rigel signs exclusive global licensing agreement for VEPPANU oral PROTAC breast cancer therapyMay 12, 2026
- Rigel published final ARROW trial data for GAVRETO in RET-positive NSCLCMar 31, 2026
- Rigel announced publication of final 5-year data on REZLIDHIA® (olutasidenib) in patients with relapsed/refractory mIDH1 AML in the Journal of Hematology & OncologyNov 17, 2025
- Rigel announces first patient enrolled in dose expansion phase of its Phase 1b study of R289 in patients with lower-risk MDSOct 9, 2025